Lucira Health, Inc. LHDX
Day range unavailable
52-week range unavailable
- Market cap
- 18.36M
- Revenue (ttm)
- 212.13M
- Profit margin
- -67.54%
- Shares out
- 40.60M
- Forward P/E
- -0.94
- Beta
- 3.76
- Analysts
- Hold
- Price target
- 0.50 (+10.5%)
- Earnings date
- Mar 9, 2023
Key statistics
- Enterprise value
- 26.68M
- PEG ratio
- 0.00
- Price / sales
- 0.09
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 129.60%
- Free cash flow
- -49.88M
- Total cash
- 39.77M
- Total debt
- 48.09M
- Return on equity
- -112.43%
- Short % of float
- 3.77%
- 50-day average
- 0.354759
- 200-day average
- 1.21
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 9, 2023
Expected Mar 9, 2023. Consensus EPS estimate -0.40.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 9, 2023 | Dec 1, 2022 | -0.33 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.38 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.30 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.08 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -0.55 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -0.51 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 4, 2021 | William Blair | down | Outperform | Market Perform |
| Apr 13, 2021 | B of A Securities | down | Buy | Underperform |
| Mar 2, 2021 | B of A Securities | init | — | Neutral |
| Mar 2, 2021 | William Blair | init | — | Outperform |
About Lucira Health, Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- lucirahealth.com
News
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
Why Is Lucira Health (LHDX) Stock Down 14% Today? 
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11 
Penny Stocks: The Importance of Liquidity and Volume 
Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week 
Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket 
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
Lucira Health shares rise more than 300% on FDA authorization of at-home combination COVID-19 and flu test 
Why Is Lucira Health (LHDX) Stock Up 237% Today?
Your note
Sign in to keep a note on LHDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN ANTHONY JOSEPH | Chief Operating Officer | Sale | Dec 19, 2022 | 144,925 |
| COLLINS KEVIN WALTER | Officer | Sale | Nov 24, 2022 | 346,722 |
| ENGELSON ERIK T. | Chief Executive Officer | Purchase | Sep 14, 2022 | 321,387 |
| GEORGE DANIEL | Chief Financial Officer | Sale | Sep 15, 2022 | 46,011 |
| HARTMANN HANSGREGORY C | Chief Operating Officer | Stock Award(Grant) | Jun 17, 2021 | 100,000 |
| KASHMOLAH GHAZI | Officer | Sale | Feb 15, 2023 | 134,075 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eclipse Ventures, LLC | 15.52% | 6,223,795 | 2.82M | Dec 30, 2022 |
| EPIQ Capital Group, LLC | 1.81% | 725,675 | 328.22K | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 1.55% | 623,488 | 282.00K | Dec 30, 2022 |
| Citigroup Inc. | 1.09% | 436,840 | 197.58K | Dec 30, 2022 |
| Balyasny Asset Management LLC | 0.68% | 271,030 | 122.59K | Dec 30, 2022 |
| Morgan Stanley | 0.52% | 207,755 | 93.97K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.16% | 464,745 | 210.20K | Sep 29, 2022 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 0.80% | 320,200 | 144.83K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.32% | 130,090 | 58.84K | Sep 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.28% | 110,500 | 49.98K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.12% | 46,406 | 20.99K | Nov 29, 2022 |
| iShares Micro Cap ETF | 0.10% | 38,198 | 17.28K | Dec 30, 2022 |